Champlain Investment Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Champlain Investment Partners’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-626,040	Closed	-$17.2M	–	122
2019 Q3	$17.2M	Sell	626,040 -960,085	-61%	-$28.4M	0.14%	111
2019 Q2	$52.5M	Buy	1,586,125 +25,610	+2%	+$877K	0.44%	92
2019 Q1	$54.7M	Sell	1,560,515 -4,670	-0.3%	-$174K	0.48%	87
2018 Q4	$52M	Buy	1,565,185 +234,480	+18%	+$10.1M	0.53%	80
2018 Q3	$67M	Buy	1,330,705 +62,450	+5%	+$3.08M	0.59%	79
2018 Q2	$75.9M	Sell	1,268,255 -6,900	-0.5%	-$357K	0.73%	62
2018 Q1	$58.4M	Buy	1,275,155 +62,370	+5%	+$2.6M	0.63%	71
2017 Q4	$48.3M	Sell	1,212,785 -17,190	-1%	-$679K	0.55%	81
2017 Q3	$49.2M	Buy	1,229,975 +484,058	+65%	+$20.9M	0.58%	75
2017 Q2	$32.1M	Buy	+745,917	New	+$26.5M	0.39%	94

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Champlain Investment Partners's SUPN Position: Q4 2019 in Review

Champlain Investment Partners sold out of Supernus Pharmaceuticals (SUPN) in Q4 2019, closing a stake of 626,040 shares — an estimated $17.2M sold.

Champlain Investment Partners first reported a position in SUPN in Q2 2017 and held it in 10 quarters. The position peaked at $75.9M in Q2 2018. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2019.

Champlain Investment Partners reported no remaining Supernus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Champlain Investment Partners sold 626,040 Supernus Pharmaceuticals shares in Q4 2019, an estimated $17.2M.
Champlain Investment Partners first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 10 quarters.
Champlain Investment Partners's Supernus Pharmaceuticals position peaked at $75.9M in Q2 2018.
235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2019.

Based on Champlain Investment Partners's 13F filing for Q4 2019, filed 13 Feb 2020.